Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $4.5 million.

  • Fulcrum Therapeutics' Net Cash Flow rose 131.84% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 159.90%. This contributed to the annual value of $32.8 million for FY2024, which is 443.56% up from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Net Cash Flow stood at $4.5 million, which was up 983.57% from $414,000 recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Net Cash Flow high stood at $50.8 million for Q3 2022, and its period low was -$55.8 million during Q4 2022.
  • In the last 3 years, Fulcrum Therapeutics' Net Cash Flow had a median value of -$768,000 in 2023 and averaged $1.1 million.
  • The largest annual percentage gain for Fulcrum Therapeutics' Net Cash Flow in the last 5 years was 6,189.58% (2024), contrasted with its biggest fall of 262.51% (2024).
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Net Cash Flow stood at -$30.1 million in 2021, then slumped by 85.76% to -$55.8 million in 2022, then soared by 91.91% to -$4.5 million in 2023, then tumbled by 219.19% to -$14.4 million in 2024, then spiked by 131.84% to $4.5 million in 2025.
  • Its Net Cash Flow stands at $4.5 million for Q3 2025, versus $414,000 for Q2 2025 and -$16.0 million for Q1 2025.